X
SRPT icon

Xponance’s Sarepta Therapeutics SRPT Stock Holding History

Xponance’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$181K Sell
10,051
-4,791
-32% -$90.6K ﹤0.01% 1633
2026
Q1 		$323K Buy
14,842
+2,342
+19% +$45.3K ﹤0.01% 1223
2025
Q4 		$269K Buy
12,500
+555
+5% +$11.7K ﹤0.01% 1235
2025
Q3 		$230K Sell
11,945
-5,950
-33% -$106K ﹤0.01% 1290
2025
Q2 		$306K Sell
17,895
-1,426
-7% -$60.8K ﹤0.01% 1137
2025
Q1 		$1.23M Buy
19,321
+608
+3% +$64K 0.01% 629
2024
Q4 		$2.28M Buy
18,713
+571
+3% +$70K 0.02% 494
2024
Q3 		$2.27M Sell
18,142
-404
-2% -$55.9K 0.02% 487
2024
Q2 		$2.93M Buy
18,546
+7,106
+62% +$913K 0.03% 415
2024
Q1 		$1.48M Sell
11,440
-288
-2% -$35.3K 0.02% 607
2023
Q4 		$1.13M Sell
11,728
-882
-7% -$84.6K 0.01% 627
2023
Q3 		$1.53M Buy
12,610
+72
+0.6% +$8.14K 0.02% 532
2023
Q2 		$1.44M Buy
12,538
+1,051
+9% +$136K 0.02% 549
2023
Q1 		$1.58M Buy
11,487
+93
+0.8% +$12.1K 0.02% 517
2022
Q4 		$1.48M Buy
11,394
+1,477
+15% +$171K 0.02% 518
2022
Q3 		$1.1M Buy
9,917
+54
+0.5% +$5.44K 0.02% 548
2022
Q2 		$739K Buy
9,863
+479
+5% +$35.2K 0.01% 689
2022
Q1 		$733K Buy
9,384
+52
+0.6% +$3.98K 0.01% 719
2021
Q4 		$840K Buy
9,332
+772
+9% +$66K 0.01% 681
2021
Q3 		$792K Sell
8,560
-345
-4% -$26.6K 0.02% 669
2021
Q2 		$692K Buy
8,905
+1,095
+14% +$83K 0.01% 763
2021
Q1 		$582K Sell
7,810
-11
-0.1% -$1.01K 0.01% 707
2020
Q4 		$1.33M Buy
7,821
+88
+1% +$13K 0.03% 395
2020
Q3 		$1.09M Sell
7,733
-39
-0.5% -$5.93K 0.03% 396
2020
Q2 		$1.25M Buy
+7,772
New +$1.06M 0.03% 340

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Xponance's SRPT Position: Q2 2026 in Review

Xponance reduced its Sarepta Therapeutics (SRPT) stake by 32% in Q2 2026, selling an estimated $90.6K and leaving 10,051 shares worth $181K. The position accounts for ﹤0.01% of the portfolio, ranked #1633.

Xponance first reported a position in SRPT in Q2 2020 and has held it in 25 quarters since. The position peaked at $2.93M in Q2 2024. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Xponance held 10,051 shares of Sarepta Therapeutics worth $181K as of Q2 2026.
  • Xponance sold 4,791 Sarepta Therapeutics shares in Q2 2026, an estimated $90.6K.
  • Sarepta Therapeutics made up ﹤0.01% of Xponance's portfolio in Q2 2026, its #1633 holding.
  • Xponance first reported a position in Sarepta Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • Xponance's Sarepta Therapeutics position peaked at $2.93M in Q2 2024.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.